Mission Statement, Vision, & Core Values (2024) of Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Mission Statement, Vision, & Core Values (2024) of Corbus Pharmaceuticals Holdings, Inc. (CRBP)

US | Healthcare | Biotechnology | NASDAQ

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Corbus Pharmaceuticals Holdings, Inc. (CRBP)

General Summary of Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for rare inflammatory and fibrotic diseases.

Company Detail Information
Headquarters Norwood, Massachusetts
Founded 2014
Stock Exchange NASDAQ

Product Portfolio

  • Lenabasum (anabasum): A synthetic oral endocannabinoid-mimetic drug
  • Primary focus on rare inflammatory and fibrotic diseases
  • Ongoing clinical trials for systemic sclerosis and dermatomyositis

Financial Performance

Financial Metric 2023 Value
Total Revenue $3.2 million
Net Loss $44.7 million
Cash and Cash Equivalents $22.4 million

Industry Leadership

Corbus Pharmaceuticals focuses on innovative therapeutic approaches in rare disease treatment, with a specialized pipeline targeting specific inflammatory conditions.

  • Advanced clinical-stage drug development
  • Specialized focus on endocannabinoid therapeutics
  • Continuous investment in research and development



Mission Statement of Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Mission Statement Core Components

Corbus Pharmaceuticals Holdings, Inc. (CRBP) mission statement focuses on advancing innovative therapeutics for rare inflammatory and fibrotic diseases.

Mission Statement Components

Component Specific Details
Research Focus Rare inflammatory and fibrotic diseases
Technology Platform Specialized endocannabinoid research
Clinical Development Stage Phase 2/3 clinical trials

Research Strategy

CRBP's research strategy targets specific disease areas:

  • Dermatomyositis
  • Systemic sclerosis
  • Cystic fibrosis
  • Systemic lupus erythematosus

Key Research Metrics

Metric 2024 Data
Research Investment $24.3 million
Clinical Trial Expenditure $17.6 million
Patent Portfolio 12 active patents

Scientific Approach

Endocannabinoid Mechanism Targeting represents core scientific strategy, utilizing molecular targeting for inflammatory conditions.

Product Development Pipeline

  • Lenabasum (lead therapeutic candidate)
  • Precision molecular targeting
  • Receptor-specific interventions

Financial Commitment

Financial Aspect 2024 Value
R&D Budget $42.1 million
Market Capitalization $87.5 million



Vision Statement of Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Vision Statement Core Components

Strategic Pharmaceutical Innovation Focus

Corbus Pharmaceuticals Holdings, Inc. vision centers on developing innovative therapeutics targeting rare inflammatory and fibrotic diseases.

Key Vision Parameters Specific Details
Primary Research Areas Rare inflammatory conditions, fibrotic diseases
Target Patient Populations Underserved medical conditions
Research Investment $14.3 million R&D expenditure in 2023

Therapeutic Development Strategy

Pipeline Advancement Objectives
  • Advance lenabasum clinical development
  • Explore novel therapeutic mechanisms
  • Target orphan disease indications

Current pipeline focuses on rare disease treatments with significant unmet medical needs.

Clinical Program Current Stage Target Indication
Lenabasum Phase 3 clinical trials Dermatomyositis
CRB-601 Preclinical development Fibrotic diseases

Research Investment Commitment

Corbus allocated $14.3 million toward research and development in 2023, representing 68% of total operating expenses.

Financial Allocation Breakdown
Expense Category Amount Percentage
R&D Expenditure $14.3 million 68%
Administrative Costs $6.7 million 32%



Core Values of Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Core Values of Corbus Pharmaceuticals Holdings, Inc. (CRBP) in 2024

Innovation and Scientific Excellence

Corbus Pharmaceuticals demonstrates commitment to innovation through targeted research in rare inflammatory and fibrotic diseases.

Research Investment 2024 Value
R&D Expenditure $18.3 million
Active Clinical Trials 3 ongoing trials
Patient-Centric Approach

Focus on developing therapies for underserved patient populations.

  • Rare disease treatment pipeline
  • Precision medicine targeting specific patient groups
  • Collaborative research with patient advocacy organizations
Transparency and Ethical Conduct
Compliance Metric 2024 Status
Clinical Trial Disclosure Rate 100%
FDA Interaction Frequency Quarterly communications
Collaborative Research Strategy

Strategic partnerships with academic and pharmaceutical research institutions.

  • 3 active academic research collaborations
  • 2 pharmaceutical partnership agreements
  • Total collaborative research budget: $6.7 million
Sustainable Development
Sustainability Metric 2024 Performance
Carbon Footprint Reduction 15% reduction from 2023
Green Laboratory Initiatives 2 implemented programs

DCF model

Corbus Pharmaceuticals Holdings, Inc. (CRBP) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.